Paul Laikind

Laikind was CEO of ViaCyte until 2020, where he lead the development of the first stem cell-derived cell therapies designed to replace pancreatic beta cells for the treatment of type 1 diabetes. Previously, he was chief business officer and senior vice president of the Sanford Burnham Medical Research Institute.

  • October 2022

Added to: Stemson Therapeutics - San Diego, CA

Stemson Therapeutics is a pre-clinical stage cell therapy company focused on regenerating hair folicles.